Showing results (1-10 of 52) with videos related to
Sort By:
Pageof 6
Cancer|June 22, 2023
The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanomaMeghan J Mooradian, Ryan J SullivanFuture Oncology (London, England)|August 5, 2017
Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeuticsMeghan J Mooradian, Ryan J SullivanOncology (Williston Park, N.Y.)|April 17, 2019
What to Do When Anti-PD-1 Therapy Fails in Patients With MelanomaMeghan J Mooradian, Ryan J SullivanCancers|August 26, 2023
Immunotherapy in Melanoma: Recent Advancements and Future DirectionsMeghan J Mooradian, Ryan J SullivanCurrent Oncology Reports|June 8, 2024
Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic SuccessMike Wang, Ryan J Sullivan, Meghan J MooradianJAMA Network Open|April 22, 2024
Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung CancerMeghan J Mooradian, Ling Cai, Alice Wang, et al.Current Oncology Reports|March 23, 2020
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical PearlsEli P Darnell, Meghan J Mooradian, Erez N Baruch, et al.European Radiology|June 3, 2021
Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitisNisanard Pisuchpen, Sienna M Durbin, Meghan J Mooradian, et al.JAMA Network Open|September 26, 2019
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United StatesSteven D Criss, Meghan J Mooradian, Tina R Watson, et al.Frontiers in Immunology|May 2, 2022
Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint TherapyAyo S Falade, Kerry L Reynolds, Leyre Zubiri, et al.Pageof 6